Pharmaceutical tablet formulation for the veterinary medical sector containing (i) benazepril or a pharmaceutically acceptable salt thereof as a first pharmaceutically active substance, and (ii) pimobendan or a pharmaceutically acceptable salt thereof as a second pharmaceutically active substance, comprising granules which contain carrier core particles coated with a first layer, wherein the first pharmaceutically active substance is present in the granules, wherein the first layer contains the first pharmaceutically active substance and a coating and/or matrix forming polymer, wherein the coated carrier core particles are additionally coated with a second layer containing at least a coating and/ or matrix forming polymer, wherein the coating polymer and/ or matrix forming polymer(s) is/are soluble under acidic conditions, but insoluble under neutral or basic conditions, and an extra-granular phase, wherein the second pharmaceutically active substance is present in the extra-granular phase, according to at least one of the following embodiments (a) to (h): (a) the pharmaceutical tablet formulation is a round, oval, polygonal or pillow-shaped tablet and optionally bears non-functional surface markings, (b) the pharmaceutical tablet formulation is a divisable tablet, (c) the pharmaceutical tablet formulation is a tablet which is divisible into two or more pieces, (d) the granules exhibit a particle size distribution where ≥90% of the particles have a diameter of 125-750 mm and/ or 50-80% of the particles have a diameter of 250-500 mm, determined by scanning electron microscope (SEM), (e) the carrier core particles comprise agglomerated α-lactose-monohydrate [Ph.Eur./USP-NF/JP] with a particle size distribution as follows: ≤ 20% <63 mm, 40-75 % < 180 mm, ≥ 85 % < 400 mm, and ≥ 97 % < 630 mm. (f) the pharmaceutical tablet formulation of the invention is packaged in a container, accompanied by a package insert providing pertinent information such as, for example, dosage and administration information, contraindications, precautions, drug interactions, and adverse reactions, (g) the pharmaceutical tablet formulation is a chewable tablet, (h) the pharmaceutical tablet formulation is a not divisable tablet. (i) benazepril or a pharmaceutically acceptable salt thereof as a first pharmaceutically active substance, and (ii) pimobendan or a pharmaceutically acceptable salt thereof as a second pharmaceutically active substance, (a) the pharmaceutical tablet formulation is a round, oval, polygonal or pillow-shaped tablet and optionally bears non-functional surface markings, (b) the pharmaceutical tablet formulation is a divisable tablet, (c) the pharmaceutical tablet formulation is a tablet which is divisible into two or more pieces, (d) the granules exhibit a particle size distribution where ≥90% of the particles have a diameter of 125-750 mm and/ or 50-80% of the particles have a diameter of 250-500 mm, determined by scanning electron microscope (SEM), (e) the carrier core particles comprise agglomerated α-lactose-monohydrate [Ph.Eur./USP-NF/JP] with a particle size distribution as follows: ≤ 20% <63 mm, 40-75 % < 180 mm, ≥ 85 % < 400 mm, and ≥ 97 % < 630 mm. (f) the pharmaceutical tablet formulation of the invention is packaged in a container, accompanied by a package insert providing pertinent information such as, for example, dosage and administration information, contraindications, precautions, drug interactions, and adverse reactions, (g) the pharmaceutical tablet formulation is a chewable tablet, (h) the pharmaceutical tablet formulation is a not divisable tablet. <EOS>